Search results for "Dali"

showing 10 items of 1372 documents

Treatment of soft tissue sarcoma in childhood and adolescence: A report of the german cooperative soft tissue sarcoma study

1992

Background In the first German soft tissue sarcoma (STS) study, CWS-81, 344 patients younger than 19 years of age who had previously untreated soft tissue sarcoma were studied. For this analysis, there were 218 patients with chemosensitive STS (Group A: rhabdomyosarcoma [RMS], synovial sarcoma, extraosseous Ewing sarcoma, leiomyosarcoma, undifferentiated sarcoma, and malignant peripheral neuroectodermal tumor) who could be studied for a minimum potential follow-up time of 6 years. Methods A staging system based on the postoperative extent of the disease was used. The chemotherapy for Stage I-III disease consisted of vincristine, dactinomycin, cyclophosphamide, and doxorubicin (VACA). Patien…

MaleReoperationLeiomyosarcomaCancer Researchmedicine.medical_specialtyVincristineAdolescentmedicine.medical_treatmentSoft Tissue NeoplasmsGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChildRhabdomyosarcomaCyclophosphamideSurvival rateNeoplasm StagingChemotherapybusiness.industrySoft tissue sarcomaSarcomaPrognosismedicine.diseaseCombined Modality TherapySurvival AnalysisSynovial sarcomaSurgeryOncologyChemotherapy AdjuvantDoxorubicinVincristineChild PreschoolDactinomycinRegression AnalysisFemaleSarcomabusinessFollow-Up Studiesmedicine.drugCancer
researchProduct

Transgraft sac Embolization Combined with Graft Reinforcement for Refractory Mixed-Type Endoleak.

2018

International audience; An 80-year-old female underwent EVAR 4 years ago. She presented type II endoleak with sac expansion from 68 to 80 mm during 3-year follow-up after EVAR. Although she underwent translumbar percutaneous sac embolization, the AAA sac continued to enlarge, suggesting mixed-type endoleak including type I, II, and III. Transgraft direct sac angiography revealed endoleak cavity without demonstrable feeding vessel. Transgraft sac embolization using n-butyl cyanoacrylate and graft reinforcement was performed concurrently, without complications. The graft reinforcement consisted of graft extension for eliminating occult type I endoleak, and relining for eliminating occult type…

MaleReoperationmedicine.medical_specialtyTransgraft sac embolizationPercutaneousEndoleakmedicine.medical_treatmentMixed typeAortographyGraft reinforcement030218 nuclear medicine & medical imaginglaw.invention03 medical and health sciencesBlood Vessel Prosthesis Implantation0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRefractoryMixed-type endoleaklawn-butyl cyanoacrylatemedicineHumansEVARRadiology Nuclear Medicine and imagingEmbolizationAged[SDV.IB] Life Sciences [q-bio]/BioengineeringAged 80 and overmedicine.diagnostic_testbusiness.industryN-butyl-cyanoacrylateEndovascular ProceduresEnbucrilateCombined Modality TherapyEmbolization Therapeutic[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemSurgeryTreatment OutcomeCyanoacrylateAngiography[SDV.IB]Life Sciences [q-bio]/BioengineeringFemaleStentsCardiology and Cardiovascular MedicinebusinessTomography X-Ray ComputedAortic Aneurysm AbdominalCardiovascular and interventional radiology
researchProduct

Brain-Derived Neurotrophic Factor But Not Forced Arm Use Improves Long-Term Outcome After Photothrombotic Stroke and Transiently Upregulates Binding …

2008

Background and Purpose— Both application of neurotrophic factors like brain-derived neurotrophic factor (BDNF) and constraint-induced movement therapy like forced arm use have been shown to potentially improve outcome after stroke. The aim of the present study was to check whether postischemic long-term outcome correlates to specific modifications in the abundance of various neurotransmitter receptors. Methods— Adult male Wistar rats were subjected to photothrombotic ischemia and assigned to various treatment groups (n=5 each) with end points at 3 and 6 weeks: (1) ischemic control (saline); (2) BDNF (ischemia, 20 μg BDNF); (3) forced arm use (ischemia, saline, and ipsilateral plaster cast …

MaleRestraint PhysicalMotor ActivityLigandsDownregulation and upregulationNeurotrophic factorsForelimbmedicineAnimalsRats WistarReceptorGABA Agonistsalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidStrokePhysical Therapy ModalitiesAdvanced and Specialized NursingBrain-derived neurotrophic factorMuscimolbusiness.industryBrain-Derived Neurotrophic FactorGlutamate receptorBrainCerebral Infarctionmedicine.diseaseRatsUp-RegulationStrokemedicine.anatomical_structureReceptors Glutamatenervous systemAnesthesiaExcitatory postsynaptic potentialAutoradiographyNeurology (clinical)Dizocilpine MaleateIntracranial ThrombosisForelimbCardiology and Cardiovascular MedicinebusinessExcitatory Amino Acid AntagonistsNeuroscienceStroke
researchProduct

Evaluation of prostate segmentation algorithms for MRI: The PROMISE12 challenge

2014

Contains fulltext : 137969.pdf (Publisher’s version ) (Open Access) Prostate MRI image segmentation has been an area of intense research due to the increased use of MRI as a modality for the clinical workup of prostate cancer. Segmentation is useful for various tasks, e.g. to accurately localize prostate boundaries for radiotherapy or to initialize multi-modal registration algorithms. In the past, it has been difficult for research groups to evaluate prostate segmentation algorithms on multi-center, multi-vendor and multi-protocol data. Especially because we are dealing with MR images, image appearance, resolution and the presence of artifacts are affected by differences in scanners and/or …

MaleScannerObserver (quantum physics)Computer scienceHealth InformaticsSensitivity and SpecificityArticleProstate cancerSegmentationImaging Three-DimensionalRobustness (computer science)Image Interpretation Computer-AssistedmedicineHumansRadiology Nuclear Medicine and imagingSegmentationChallengeProtocol (science)Modality (human–computer interaction)Radiological and Ultrasound TechnologyProstateProstatic NeoplasmsReproducibility of ResultsReference Standardsmedicine.diseaseImage EnhancementComputer Graphics and Computer-Aided DesignMagnetic Resonance ImagingActive appearance modelUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Computer Vision and Pattern RecognitionArtifactsAlgorithmAlgorithmsRare cancers Radboud Institute for Health Sciences [Radboudumc 9]MRI
researchProduct

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.

2013

Objective Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti–tumor necrosis factor α (anti-TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease-modifying antirheumatic drugs. Methods Patients were identified from 15 outpatient clinics of university hospitals and hospitals in Italy taking part in the Gruppo Italiano di Studio sulle Early Arthritis network. Disease Activity Score in 28 joints (DAS28), body mass index (BMI; categorized …

MaleSettore MED/16 - REUMATOLOGIAArthritisGastroenterologyReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidRheumatoidMonoclonalReceptorsMedicineOutpatient clinicLongitudinal StudiesRegistriesPrecision Medicineskin and connective tissue diseasesHumanizedRemission InductionAntibodies MonoclonalIndividualized MedicineMiddle AgedTreatment OutcomeRheumatoid arthritisAntirheumatic AgentsFemaleDrugmedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyAdalimumab; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Longitudinal Studies; Male; Middle Aged; Obesity; Precision Medicine; Receptors Tumor Necrosis Factor; Registries; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alphaAntibodies Monoclonal HumanizedAntibodiesDose-Response RelationshipRheumatologyInternal medicineAdalimumabHumansObesityRisk factorAgedDose-Response Relationship Drugbusiness.industryTumor Necrosis Factor-alphaArthritisAdalimumabmedicine.diseaseInfliximabRheumatologyInfliximabAged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Female; Humans; Immunoglobulin G; Individualized Medicine; Longitudinal Studies; Male; Middle Aged; Obesity; Receptors Tumor Necrosis Factor; Registries; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alphaImmunoglobulin GImmunologybusinessTumor Necrosis FactorArthritis careresearch
researchProduct

Rare association of herpes simplex virus IgM-specific antibodies and Guillain-Barré syndrome successfully treated with plasma exchange and immunosupp…

1985

Herpes simplex virus (HSV) has been associated with various neurological disorders. In contrast, HSV infection is very rarely found in acute polyneuroradiculitis. In this report, a patient is described with a severe course of Guillain-Barr¿ syndrome (GBS). HSV IgM-specific antibodies and a rise of complement-fixation antibodies were detected. During the acute phase of neurologic syndrome, a nerve biopsy showed myelin damage and IgM deposits on the inner layer of the perineurium. Plasma exchange, in combination with immunosuppression, was successfully applied as a treatment in the relapsing course of GBS. Finally, after recovery, HSV-specific IgM antibodies disappeared.

MaleSimplexvirusfood.ingredientBiopsyPrednisolonevirusesmedicine.medical_treatmentNeural ConductionPolyradiculoneuropathyAntibodies Viralmedicine.disease_causefoodSural NerveAntibody SpecificityAzathioprineDrug DiscoverymedicineHumansSimplexvirusGenetics (clinical)AgedNerve biopsyPlasma ExchangeGuillain-Barre syndromemedicine.diagnostic_testbiologyHerpes SimplexImmunosuppressionPolyradiculoneuropathyGeneral Medicinemedicine.diseaseCombined Modality TherapyVirologyHerpes simplex virusImmunoglobulin MImmunoglobulin MImmunologybiology.proteinMolecular MedicineAntibodyKlinische Wochenschrift
researchProduct

Detrimental Effects of 60 kHz Sonothrombolysis in Rats with Middle Cerebral Artery Occlusion

2008

Recent studies have raised concerns about the safety of low frequency ultrasound in transcranial therapeutic application in cerebral ischemia. This study was designed to evaluate safety aspects and potential deleterious effects of low frequency, 60 kHz ultrasound in treatment of experimental middle cerebral artery occlusion (MCAO) in rats. Forty-five male Wistar rats were submitted to either temporary (90 min; groups I and II) or permanent MCAO (groups III and IV) using the suture technique. All animals received recombinant tissue plasminogen activator (rt-PA) starting 90 min after the beginning of occlusion. Groups I and III were additionally treated with 60 kHz ultrasound (time average ac…

MaleSubarachnoid hemorrhageAcoustics and UltrasonicsUltrasonic Therapymedicine.medical_treatmentBiophysicsIschemiaOcclusionmedicineAnimalsThrombolytic TherapyRadiology Nuclear Medicine and imagingRats WistarHearing DisordersStrokeCerebral HemorrhageRadiological and Ultrasound TechnologyTherapeutic ultrasoundmedicine.diagnostic_testbusiness.industryUltrasoundTemperatureInfarction Middle Cerebral ArteryMagnetic resonance imagingSubarachnoid Hemorrhagemedicine.diseaseCombined Modality TherapyMagnetic Resonance ImagingRatsTreatment OutcomeAnesthesiabusinessPerfusionUltrasound in Medicine & Biology
researchProduct

Rationale and results of the international society of pediatric oncology (SIOP) Italian pilot study on childhood hepatoma: Surgical resectionD'Emblée…

1993

MaleSurgical resectionPediatricsmedicine.medical_specialtyCarcinoma HepatocellularAdolescentBiopsyPilot ProjectsChildhood HepatomaAntineoplastic Combined Chemotherapy ProtocolsPreoperative CarePediatric oncologymedicineHepatectomyHumansPrimary chemotherapyChildbusiness.industryLiver NeoplasmsRemission InductionInfantGeneral MedicineCombined Modality TherapySurvival RateItalyOncologyDoxorubicinChild PreschoolFemaleSurgeryCisplatinbusinessFollow-Up StudiesJournal of Surgical Oncology
researchProduct

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspi…

2009

The prognosis for thalassemia major has dramatically improved in the last two decades. However, many transfusion-dependent patients continue to develop progressive accumulation of iron. This can lead to tissue damage and eventually death, particularly from cardiac disease. Previous studies that investigated iron chelation treatments, including retrospective and prospective non-randomised clinical trials, suggested that mortality, due mainly to cardiac damage, was reduced or completely absent in patients treated with deferiprone (DFP) alone or a combined deferiprone-deferoxamine (DFP-DFO) chelation treatment. However, no survival analysis has been reported for a long-term randomised control …

MaleThalassemiaKaplan-Meier Estimatelaw.inventionchemistry.chemical_compoundRandomized controlled triallawCause of DeathNeoplasmsDeferiproneProspective StudiesChildCause of deathHazard ratioHematologyMiddle AgedCombined Modality TherapySurvival RateThalassemia survival chelation treatment trial thalassemia majorCombinationSplenectomyMolecular MedicineDrug Therapy CombinationFemaleDeferiproneAdultmedicine.medical_specialtyAdolescentPyridonesDeferoxamineIron Chelating AgentsYoung AdultDrug TherapyInternal medicinemedicineHumansBlood TransfusionAdolescent; Adult; Blood Transfusion; Cause of Death; Chelation Therapy; Child; Combined Modality Therapy; Deferoxamine; Drug Therapy; Combination; Female; Heart Failure; Humans; Iron Chelating Agents; Kaplan-Meiers Estimate; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Prospective Studies; Pyridones; Splenectomy; Survival Rate; Young Adult; beta-ThalassemiaMolecular BiologySurvival rateKaplan-Meiers EstimateSurvival analysisProportional Hazards ModelsHeart Failurebusiness.industryProportional hazards modelbeta-ThalassemiaCell Biologymedicine.diseaseChelation TherapySurgerychemistrybusiness
researchProduct

Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Regist…

2012

Objective.To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimumab, etanercept, and infliximab among patients with longstanding rheumatoid arthritis (RA), as derived from an Italian national registry.Methods.The clinical records of 853 adult patients with RA in the GISEA (Gruppo Italiano Studio Early Arthritis) registry were prospectively analyzed to compare drug survival rates and the baseline factors that may predict adherence to therapy.Results.In 2003 and 2004, 324 patients started treatment with adalimumab, 311 with etanercept, and 218 with infliximab. After 4 years, the global retention rate of anti-TNF-α therapy was 42%. Etanercept survival (51.4%) …

MaleTime FactorsHealth StatusArthritisKaplan-Meier EstimateReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptArthritis RheumatoidRandomized controlled triallawRheumatoidMonoclonalReceptorsImmunology and AllergyProspective StudiesRegistriesskin and connective tissue diseasesProspective cohort studyHumanizedAntibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biological Markers; Drug Substitution; Female; Health Status; Humans; Immunoglobulin G; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesPain MeasurementDrug SubstitutionAntibodies MonoclonalMiddle AgedArthralgiaAdalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesSurvival RateItalyRheumatoid arthritisAntirheumatic AgentsBiological MarkersAdalimumab; Drug survival; Etanercept; Infliximab; Adalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; Registries; Rheumatology; Immunology; Immunology and AllergyFemalemedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyImmunologyAntibodies Monoclonal HumanizedAntibodiesRheumatologyDrug survivalInternal medicineAdalimumabmedicineHumansSurvival ratebusiness.industryTumor Necrosis Factor-alphaArthritisAdalimumabmedicine.diseaseInfliximabInfliximabSurgeryImmunoglobulin GJointsbusinessTumor Necrosis FactorBiomarkers
researchProduct